Journal List > Korean J Gastroenterol > v.60(5) > 1007015

Kim: Comparison of Efficacy of Peginterferon and Ribavirin Combination Therapy for Chronic Hepatitis C among Korean, Caucasian and Other Asians


Financial support: None.

Conflict of interest: None.


1. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002. 36:5 Suppl 1. S35–S35.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009. 49:1335–1374.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011. 55:245–264.
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011. 54:1433–1444.
5. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009. 24:336–345.
6. Roberts SK, Weltman MD, Crawford DH, et al. Chariot Study Group. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology. 2009. 50:1045–1055.
7. Park SY, Rim MY, Yo IK, et al. Efficacy of peg-interferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis. Korean J Gastroenterol. 2012. 60:306–314.
8. Kim MN, Yoon KT, Park JY, et al. A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C. Korean J Hepatol. 2009. 15:496–503.
9. Park SH, Park CK, Lee JW, et al. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver. 2012. 6:98–106.
Similar articles